701 related articles for article (PubMed ID: 31088111)
21. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC; Brown DM; Maldonado ME; Croft DE
Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
[TBL] [Abstract][Full Text] [Related]
22. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.
DeCroos FC; Reed D; Adam MK; Salz D; Gupta OP; Ho AC; Regillo CD
Am J Ophthalmol; 2017 Aug; 180():142-150. PubMed ID: 28624325
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
24. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
25. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG
Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration.
Ayachit A; Singh SR; Subramanyam A; Tiwari S; Heranjal A; Chattannavar G; Pandey P; Salti H; Mansour MA; Mansour A; Chhablani J
Asia Pac J Ophthalmol (Phila); 2020; 9(2):144-148. PubMed ID: 32175924
[TBL] [Abstract][Full Text] [Related]
27. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
28. ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).
Korobelnik JF; Souied EH; Oubraham H; Razavi S; Mauget-Faÿsse M; Savel H; Chene G; Wolf S
Retina; 2021 Mar; 41(3):588-594. PubMed ID: 33600134
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
[TBL] [Abstract][Full Text] [Related]
30. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.
Aghdam KA; Pielen A; Framme C; Junker B
Eur J Ophthalmol; 2016 Aug; 26(5):473-8. PubMed ID: 26868007
[TBL] [Abstract][Full Text] [Related]
31. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
Sekfali R; Mimoun G; Cohen SY; Querques G; Bandello F; Sacconi R; Souied EH; Capuano V
Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
[TBL] [Abstract][Full Text] [Related]
32. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
33. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
[TBL] [Abstract][Full Text] [Related]
34. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
[TBL] [Abstract][Full Text] [Related]
35. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
36. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
37. SAVING SIGHT IN NEOVASCULAR AMD.
Retina; 2020 Jul; 40 Suppl 2():S1-S12. PubMed ID: 32558673
[No Abstract] [Full Text] [Related]
38. The VEGF Treatment of AMD Switch Study (The vTAS Study).
Curry B; Bylsma G; Hewitt AW; Verma N
Asia Pac J Ophthalmol (Phila); 2017; 6(6):481-487. PubMed ID: 29204996
[TBL] [Abstract][Full Text] [Related]
39. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
40. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
